Multiple myeloma trials in Hungary

In Hungary 7 Also abroad 704

7 of 7 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Where
Budapest IX, Budapest XII, Debrecen, Eger, Győr, Szeged, Székesfehérvár, Szekszárd
Age
18 years and over
People
386 worldwide
Run by
Grifols Therapeutics LLC
See details and how to joinNCT05645107 · EU 2022-502193-16-00
Phase 2Taking people
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Where
Budapest, Pécs, Szeged
Age
18 years and over
People
230 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07589634
Phase 3Taking people
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Where
Budapest IX, Debrecen
Age
18 years and over
People
440 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00
Phase 3Taking people
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Where
Budapest VIII, Debrecen, Kaposvár, Szombathely
Age
18 years and over
People
183 worldwide
Run by
Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00
Phase 1/2Taking people
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Where
Budapest VIII, Budapest XII, Pécs
Age
18 years and over
People
78 worldwide
Run by
Heidelberg Pharma AG
See details and how to joinNCT04879043 · EU 2024-515273-10-00
Phase 2Taking people
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
Where
Budapest IX, Budapest VIII, Budapest XII, Debrecen, Pécs, Szeged
Age
18 years and over
People
123 worldwide
Run by
Janssen Cilag International
See details and how to join2025-524793-42-00
Phase 3Not yet taking people in Hungary
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Where
Szombathely
Age
18 years and over
People
520 worldwide
Run by
AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00